MedTrace Logo

Study of AggreGuide A-100 (ADP) Assay

NCT03111420 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2019-02-21

No results posted yet for this study

Summary

Study to evaluate the performance of the AggreGuide A-100 ADP assay for detection of platelet dysfunction caused by P2Y12 inhibitor antiplatelet therapy.

Conditions

  • Risk Factor, Cardiovascular
  • Platelet Dysfunction Due to Drugs

Interventions

DRUG

P2Y12 inhibitor

Administration of P2Y12 inhibitor antiplatelet therapy

DEVICE

Platelet function test

Blood is drawn for testing of platelet aggregation activity

Sponsors & Collaborators

  • Aggredyne, Inc.

    lead INDUSTRY

Principal Investigators

  • Phil Speros · Aggredyne, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
22 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-09
Primary Completion
2018-06-30
Completion
2018-06-30
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03111420 on ClinicalTrials.gov